重组人促红细胞生成素治疗癌性贫血31例临床观察

目的:观察重组人红细胞生成素(rhEPO)治疗癌性贫血的疗效和不良反应。方法:非髓性癌性贫血患者31例,皮下注射rhEPO100 U/kg.次,每周3次,连续8周,比较治疗前后血红蛋白(Hb)、红细胞比容(HCT)和KPS评分的变化。结果:30例可评价疗效患者,其中19例Hb上升≥20 g/L或Hb≥120 g/L,HCT比值也明显上升(P<0.01)。KPS评分增加者达86.7%。不良反应轻微,3例出现血压轻度升高。结论:rhEPO能明显提高非髓性癌性贫血患者的Hb水平,改善体力和生活质量,不良反应少且使用安全。

Efficacy and safety of recombinant human erythropoietin (rhEPO) for 31 anemic non-myeloid cancer patients

Objective To evaluate the safety and effects of recombinant human erythropoietin（rhEPO） f or anemic non-myeloid cancer patients.Method A total of 31 anemic non-myeloid cancer patients were enrolle d in this study,patients received rhEPO at a dose of 100 U/kg each time subcutan eously,three times a week for 8 weeks.Patients′ Hb,HCT and KPS before and af ter rhEPO treatment were compared and side effects were recorded.Results Amony the 30 patients evaluata ble for hematological response,19 had an increase in Hb≥20 g/L or displayed H b≥120 g/L.The same in HCT.86.7% of them increased KPS.The sids effects wer e a slightly improved of blood pressure of three patients.Co n clusion rhEPO increases Hb and improves the perfo rmance status and quality of life in anemic non-myeloid cancer patients with lim ited side effects.